Ptc Therapeutics, INC 10-Q quarterly reports

PTC Therapeutics announces robust Q2 2026 financial results, with significant revenue growth driven by Sephience, alongside strategic advancements in its pipeline and a strengthened financial position.

PTC Therapeutics reported a significant increase in net product revenue for Q1 2026, driven by Sephience sales, while continuing to advance its diverse pipeline and manage operational expenses.

PTC Therapeutics achieved significant net income and revenue growth in Q3 2025, primarily driven by a $1.0 billion upfront payment from its Novartis collaboration, despite product revenue declines for Translarna and Emflaza.

PTC Therapeutics reported a significant financial turnaround driven by a $1.0 billion upfront payment from Novartis, alongside key regulatory approvals for its PKU treatment, Sephience, despite challenges with Translarna in Europe.

PTC Therapeutics' Q1 2025 results showcase a significant revenue surge due to a collaboration with Novartis, offsetting declines in product sales.

PTC Therapeutics' Q3 2024 results show a decrease in product revenue and an increase in royalty revenue, while facing regulatory challenges for Translarna in Europe.

PTC Therapeutics' Q2 2024 results show a decrease in revenue compared to the same period last year, alongside strategic adjustments in research and development.

PTC Therapeutics' first quarter 2024 results show a decrease in net product revenue and increased operating expenses, while the company navigates regulatory challenges for its key drug, Translarna.